|
28 Nov 2020 |
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
|
|
27 Nov 2020 |
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
|
|
26 Nov 2020 |
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
|
|
26 Nov 2020 |
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modification
|
|
26 Nov 2020 |
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
|
|
25 Nov 2020 |
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
|
|
24 Nov 2020 |
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
|
|
23 Nov 2020 |
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
|
|
23 Nov 2020 |
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
|
|
23 Nov 2020 |
Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma
|
|
23 Nov 2020 |
Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
|
|
22 Nov 2020 |
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
|
|
22 Nov 2020 |
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
|
|
20 Nov 2020 |
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
|
|
20 Nov 2020 |
Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
|
|
20 Nov 2020 |
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
|
|
19 Nov 2020 |
Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference
|
|
19 Nov 2020 |
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
|
|
19 Nov 2020 |
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
|
|
19 Nov 2020 |
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
|
|
18 Nov 2020 |
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
|
|
18 Nov 2020 |
PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study
|
|
18 Nov 2020 |
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100
|
|
17 Nov 2020 |
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
|
|
17 Nov 2020 |
Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus
|
